1 Hospital del Mar, Barcelona, Spain. 2 Hospital Universitario La Paz, Madrid, Spain. 3 Hospital Universitario General de Alicante, Alicante, Spain. 4 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. 5 Hospital Son Espases, Mallorca, Spain. 6 Hospital Universitario Virgen del Rocío, Sevilla, Spain. 7 Complejo Hospitalario Universitario Santiago, Santiago de Compostela, Spain. 8 Ciutat Sanitaria i Universitaria de Bellvitge, l'Hospitalet de Llobregat, Spain. 9 Hospital Regional Universitario Carlos Haya, Málaga, Spain. 10 Hospital 12 de Octubre, Madrid, Spain. 11 Hospital Universitario Dr. Peset, Valencia, Spain. 12 Hospital General Vall d'Hebron, Barcelona, Spain. 13 Hospital Universitario Marques de Valdecilla, Santander, Spain. 14 Hospital Clínic, Universidad de Barcelona, Institut d'Investigacions August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Transplantation. 2013 Oct 27;96(8):717-25. doi: 10.1097/TP.0b013e31829f162e.
The association of anemia with outcomes after renal transplantation (RT) is unclear.
We performed a retrospective study that included patients who received a RT in Spain in 2007. We collected data on anemia (hemoglobin [Hb] <11 g/dL and/or erythropoietic agents and/or transfusion in the previous month) as well as transplantation and clinical data during follow-up. We used multivariate Cox models to predict graft and patient survival.
We included 639 patients; 7.2% lost their graft and 6.3% died. The prevalence of anemia was 84% at 7 days, 77% at 1 month, 41% at 2 months, 16% at 12 months, 14% at 24 months, and 18% at 36 months. After adjusting by glomerular filtration rate (hazard ratio [95% confidence interval], 0.96 [0.93-0.98]), low Hb levels at 1 month remained as an independent predictor of graft loss (hazard ratio for each 1 g/dL increase, 0.72 [0.54-0.96]) along with a maximum panel-reactive antibody of more than 10% (3.80 [1.73-8.36]), a donor with stroke (3.30 [1.31-8.28]), and one or more acute rejection episode (13.89 [4.78-40.37]). Tacrolimus use was a protective factor (0.24 [0.11-0.50]).
Low Hb levels in the early posttransplantation period (1 month) seem to be an independent prognostic factor for graft loss, but not for mortality, in Spanish RT patients regardless of graft function, recipient and donor characteristics, unfavorable events within the first month, and immunosuppression.
贫血与肾移植(RT)后结局的关系尚不清楚。
我们进行了一项回顾性研究,纳入了 2007 年在西班牙接受 RT 的患者。我们收集了移植前 1 个月内的贫血(血红蛋白[Hb]<11g/dL 和/或使用促红细胞生成素和/或输血)以及移植和临床数据。我们使用多变量 Cox 模型预测移植物和患者的存活率。
我们纳入了 639 例患者;7.2%的患者移植失败,6.3%的患者死亡。移植后第 7 天、第 1 个月、第 2 个月、第 12 个月、第 24 个月和第 36 个月时贫血的患病率分别为 84%、77%、41%、16%、14%和 18%。在调整肾小球滤过率(危险比[95%置信区间],0.96[0.93-0.98])后,第 1 个月时 Hb 水平较低仍然是移植失败的独立预测因素(每增加 1g/dL 的危险比为 0.72[0.54-0.96]),同时还有 panel-reactive antibody 最大值超过 10%(3.80[1.73-8.36])、供者有中风(3.30[1.31-8.28])和 1 次或多次急性排斥反应(13.89[4.78-40.37])。他克莫司的使用是一个保护因素(0.24[0.11-0.50])。
无论移植肾功能、受者和供者特征、移植后 1 个月内的不良事件以及免疫抑制情况如何,西班牙 RT 患者移植后早期(1 个月)Hb 水平较低似乎是移植失败的独立预后因素,但不是死亡的独立预后因素。